Chemomab Therapeutics (CMMB) Share-based Compensation (2018 - 2023)
Chemomab Therapeutics' (CMMB) quarterly Share-based Compensation came in at $238000.0 in Q4 2023, down 67.84% YoY from $740000.0 in Q4 2022, and up 83.08% on a QoQ basis from $130000.0 in Q3 2023.
Chemomab Therapeutics (CMMB) Share-based Compensation (2018 - 2023) Analysis & Trends
Chemomab Therapeutics (CMMB) has 6 years of Share-based Compensation data on file, last reported at $238000.0 in Q4 2023.
- Quarterly Share-based Compensation fell 67.84% year-over-year to $238000.0 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $1.5 million (down 53.57% YoY) and the FY2025 annual result came in at $623000.0, up 0.97% from the prior year.
- Share-based Compensation improved to $238000.0 in Q4 2023, from $130000.0 in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $1.0 million in Q4 2021 to a low of $23000.0 in Q3 2020.
- A 5-year average of $405600.0 and a median of $374000.0 in 2019 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2020 — Share-based Compensation slumped 92.83% — and 2022, when it soared 1932.56%.
- Tracing CMMB's Share-based Compensation over 5 years: stood at $89000.0 in 2019, then jumped by 52.81% to $136000.0 in 2020, then jumped by 641.18% to $1.0 million in 2021, then slipped by 26.59% to $740000.0 in 2022, then plunged by 67.84% to $238000.0 in 2023.
- The last three Share-based Compensation figures came in at $238000.0 (Q4 2023), $130000.0 (Q3 2023), and $639000.0 (Q2 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.04 Bn | 130.18 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 85.98 Bn | 77.98 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.37 Bn | 59.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.67 Bn | 52.53 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.94 Bn | 36.84 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 27.75 Bn | 9.35 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.24 Bn | 26.08 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.03 Bn | 26.20 Bn | - | - |
| 10 | Chemomab Therapeutics | 13.49 Mn | 3.12 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 238,000.00 |
| Dec 31, 2023 | 238,000.00 |
| Sep 30, 2023 | 130,000.00 |
| Sep 30, 2023 | 130,000.00 |
| Jun 30, 2023 | 639,000.00 |
| Jun 30, 2023 | 639,000.00 |
| Mar 31, 2023 | 484,000.00 |
| Mar 31, 2023 | 484,000.00 |
| Dec 31, 2022 | 740,000.00 |
| Dec 31, 2022 | 740,000.00 |
| Sep 30, 2022 | 836,000.00 |
| Sep 30, 2022 | 836,000.00 |
| Jun 30, 2022 | 761,000.00 |
| Jun 30, 2022 | 761,000.00 |
| Mar 31, 2022 | 874,000.00 |
| Mar 31, 2022 | 874,000.00 |
| Dec 31, 2021 | 1.01 Mn |
| Dec 31, 2021 | 1.01 Mn |
| Sep 30, 2021 | 441,000.00 |
| Sep 30, 2021 | 441,000.00 |